Skip to content

Study · Observational study · n = 82 · 2012

6 results

The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.

Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, Tagawa K, Omata M, Koike K

TheScientificWorldJournal13 Aug 2012Cited by 106 (Europe PMC)

PMID22927782 (opens in a new tab)PMCIDPMC3425807 (opens in a new tab)DOI10.1100/2012/496453 (opens in a new tab)PepBankPUB-22927782
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

BACKGROUND. Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients. AIMS. The aim of this study is to elucidate the effectiveness of liraglutide in NAFLD patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and pioglitazone. METHODS. We retrospectively enrolled 82 Japanese NAFLD patients with T2DM and divided into three groups (liraglutide: N = 26, sitagliptin; N = 36, pioglitazone; N = 20). We compared the baseline characteristics, changes of laboratory data and body weight. RESULTS. At the end of follow-up, ALT, fast blood glucose, and HbA1c level significantly improved among the three groups. AST to platelet ratio significantly decreased in liraglutide group and pioglitazone group. The body weight significantly decreased in liraglutide group (81.8 kg to 78.0 kg, P < 0.01). On the other hands, the body weight significantly increased in pioglitazone group and did not change in sitagliptin group. Multivariate regression analysis indicated that administration of liraglutide as an independent factor of body weight reduction for more than 5% (OR 9.04; 95% CI 1.12-73.1, P = 0.04). CONCLUSIONS. Administration of liraglutide improved T2DM but also improvement of liver inflammation, alteration of liver fibrosis, and reduction of body weight.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In Japanese patients with NAFLD and type 2 diabetes, liraglutide was an independent factor for weight reduction of more than 5% (OR 9.04).

    In plain wordsIn Japanese people with fatty liver and type 2 diabetes, liraglutide was linked to losing more than 5% of body weight.

    Peptide
    Liraglutide
    Outcome
    IncreaseWeight reduction of more than 5% (multivariate regression)
    Study

    n = 82

    Comparator
    Sitagliptin and pioglitazone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    9.04
    weight reduction >5%, 95% CI 1.12-73.1

    Source sentences

    Summary
    Multivariate regression analysis indicated that administration of liraglutide as an independent factor of body weight reduction for more than 5% (OR 9.04; 95% CI 1.12-73.1, P = 0.04).
    2 context sentences
    Summary · context
    We retrospectively enrolled 82 Japanese NAFLD patients with T2DM and divided into three groups (liraglutide: N = 26, sitagliptin; N = 36, pioglitazone; N = 20).
    Summary · context
    We compared the baseline characteristics, changes of laboratory data and body weight.
  2. 02HumanObservational studyEfficacy outcome

    In Japanese patients with NAFLD and type 2 diabetes, ALT improved significantly by the end of follow-up, in the three groups including liraglutide.

    In plain wordsIn Japanese people with fatty liver and type 2 diabetes, liver enzyme ALT improved over follow-up, including with liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseALT change
    Study

    n = 26

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At the end of follow-up, ALT, fast blood glucose, and HbA1c level significantly improved among the three groups.
    2 context sentences
    Summary · context
    We retrospectively enrolled 82 Japanese NAFLD patients with T2DM and divided into three groups (liraglutide: N = 26, sitagliptin; N = 36, pioglitazone; N = 20).
    Summary · context
    We compared the baseline characteristics, changes of laboratory data and body weight.
  3. 03HumanObservational studyEfficacy outcome

    In Japanese patients with NAFLD and type 2 diabetes, fasting blood glucose improved significantly by the end of follow-up, in the three groups including liraglutide.

    In plain wordsIn Japanese people with fatty liver and type 2 diabetes, fasting blood sugar improved over follow-up, including with liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting blood glucose change
    Study

    n = 26

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At the end of follow-up, ALT, fast blood glucose, and HbA1c level significantly improved among the three groups.
    2 context sentences
    Summary · context
    We retrospectively enrolled 82 Japanese NAFLD patients with T2DM and divided into three groups (liraglutide: N = 26, sitagliptin; N = 36, pioglitazone; N = 20).
    Summary · context
    We compared the baseline characteristics, changes of laboratory data and body weight.
  4. 04HumanObservational studyEfficacy outcome

    In Japanese patients with NAFLD and type 2 diabetes, HbA1c improved significantly by the end of follow-up, in the three groups including liraglutide.

    In plain wordsIn Japanese people with fatty liver and type 2 diabetes, HbA1c improved over follow-up, including with liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change
    Study

    n = 26

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At the end of follow-up, ALT, fast blood glucose, and HbA1c level significantly improved among the three groups.
    2 context sentences
    Summary · context
    We retrospectively enrolled 82 Japanese NAFLD patients with T2DM and divided into three groups (liraglutide: N = 26, sitagliptin; N = 36, pioglitazone; N = 20).
    Summary · context
    We compared the baseline characteristics, changes of laboratory data and body weight.
  5. 05HumanObservational studyEfficacy outcome

    In Japanese patients with NAFLD and type 2 diabetes, the AST to platelet ratio decreased significantly in the liraglutide group (and in the pioglitazone group).

    In plain wordsIn Japanese people with fatty liver and type 2 diabetes, a liver scarring marker fell with liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseAST to platelet ratio change
    Study

    n = 26

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    AST to platelet ratio significantly decreased in liraglutide group and pioglitazone group.
    2 context sentences
    Summary · context
    We retrospectively enrolled 82 Japanese NAFLD patients with T2DM and divided into three groups (liraglutide: N = 26, sitagliptin; N = 36, pioglitazone; N = 20).
    Summary · context
    We compared the baseline characteristics, changes of laboratory data and body weight.
  6. 06HumanObservational studyEfficacy outcome

    In Japanese patients with NAFLD and type 2 diabetes, body weight decreased significantly in the liraglutide group, from 81.8 kg to 78.0 kg.

    In plain wordsIn Japanese people with fatty liver and type 2 diabetes, body weight fell from 81.8 kg to 78.0 kg with liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 26

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Body weight
    81.8 kg
    before, liraglutide
    Body weight
    78 kg
    after, liraglutide

    Source sentences

    Summary
    The body weight significantly decreased in liraglutide group (81.8 kg to 78.0 kg, P < 0.01).
    2 context sentences
    Summary · context
    We retrospectively enrolled 82 Japanese NAFLD patients with T2DM and divided into three groups (liraglutide: N = 26, sitagliptin; N = 36, pioglitazone; N = 20).
    Summary · context
    We compared the baseline characteristics, changes of laboratory data and body weight.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.